CMPX today
$0.81-$0.02 (-2.02%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourExpanding
1 hourBearish
15 minDescending Triangle
5 minStrong Bearish
Daily trend turns up above $0.81
Key levels
Resistance$1.05
Resistance$0.90
Support$0.81
Support$0.67
Latest news & SEC filings
AnalystWedbush keeps Neutral rating on Compass Therapeutics, cuts price target to $0.9
EarningsCompass Therapeutics Posts Q3 2026 Financials
All CMPX news →About Compass Therapeutics
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on oncology. It develops antibody-based treatments aimed at angiogenesis, immune activation, and tumor evasion mechanisms. Its pipeline includes four clinical candidates, including bispecific and agonistic antibodies, targeting solid tumors and blood cancers. The company operates in the United States.
Based on the company's 10-K filed Mar 5, 2026.
Nasdaq · Healthcare
Compass Therapeutics, Inc. (CMPX)
What Is the Price Target for CMPX?
SEPT Low Target
$1.00
SEPT Mid Target
$4.00
SEPT High Target
$7.00
Analyst Consensus
$4.00
Is CMPX a Buy or Sell Right Now?
Thesis
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CMPX.
Start Free Trial →Is CMPX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$4.00
12
Moat Score
NONE
4/9
Piotroski Score
0.1
Altman Z-Score
What Is Smart Money Doing with CMPX?
Insider Signal
BUYING
4 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Lerner Neil | officer | Buy | 20,000 | $18K | Oct 1, 2026 |
| Lerner Neil | officer | Buy | 2,500 | $3K | Sep 24, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CMPX Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
-9.5%
Revenue Trend
UNKNOWN
Dark Pool Trades for CMPX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CMPX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:05:23 | $0.81 | 2,000 | $$2K | MIDPOINT |
| 17:58:29 | $0.82 | 12,400 | $$10K | BUY |
| 17:58:07 | $0.82 | 2,700 | $$2K | SELL |
| 17:58:07 | $0.82 | 2,700 | $$2K | SELL |
| 17:42:08 | $0.81 | 4,000 | $$3K | SELL |
5 dark pool trades shown · $$19K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for CMPX
PREVIEWSEPT Investing provides real-time options flow tracking for CMPX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $1 | Nov 20 | 8 | $$1260 | 420 | BLOCK |
| CALL | $1 | Dec 18 | 36 | $$2940 | 420 | BLOCK |
| CALL | $1 | Dec 18 | 36 | $$24 | 3 | SWEEP |
| CALL | $1 | Nov 20 | 8 | $$6 | 3 | SWEEP |
| CALL | $1 | Dec 18 | 36 | $$24 | 3 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About CMPX
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for CMPX. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Smart Money Moves $IBO — DSS, INC. | Sale $1K $STKS — HILARIO EMANUEL N | Sale $18K $ONDS — LAIRD NEIL J | Sale $ONDS — LAIRD NEIL J | Sale $38K $CMPX — Lerner Neil | Sale $3K
Join 3,500+ traders discussing CMPX in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Compass Therapeutics, Inc. (CMPX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CMPX — frequently asked questions
What is CMPX stock price today?
Compass Therapeutics, Inc. (CMPX) is at $0.81, down 2.02% (-$0.02) at the Nov 12, 2026 close.
Why is CMPX stock moving today?
Latest CMPX news — Nov 10, 2026: Wedbush keeps Neutral rating on Compass Therapeutics, cuts price target to $0.9 · Nov 9, 2026: Compass Therapeutics Posts Q3 2026 Financials
What is the CMPX price target?
The average analyst price target for CMPX is $4.00, ranging from $1 to $7, based on 5 analysts. Latest: Citizens maintains on Sep 23, 2026.
What do analysts rate CMPX?
Analyst ratings for CMPX: 0 Buy, 8 Hold, 1 Sell — consensus Hold.
Did CMPX beat earnings?
CMPX last reported on Aug 6, 2026: EPS -$0.13 vs -$0.11 expected — a miss of 17.4%.
Does CMPX pay a dividend?
CMPX does not currently pay a dividend.
What are CMPX support and resistance levels?
Support: $0.81, $0.67. Resistance: $0.90, $1.05, $1.19.
What are insiders doing with CMPX?
Insider activity: BUYING, 4 buys and 0 sells in the last 90 days.
What is the latest news on CMPX?
Nov 10, 2026: Wedbush keeps Neutral rating on Compass Therapeutics, cuts price target to $0.9 · Nov 9, 2026: Compass Therapeutics Posts Q3 2026 Financials